Treatment of functional dyspepsia using asimadoline

Abstract

The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the said pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the said pharmaceutical composition.

1 - 23 . (canceled)  
     
     
         24 . A method for treating functional dyspepsia in a human comprising administering an effective amount of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride to a human having functional dyspepsia.  
     
     
         25 . The method of  claim 24 , wherein said administration influences satiety.  
     
     
         26 . The method of  claim 24 , wherein said administration influences one or more post-prandial symptoms.  
     
     
         27 . The method of  claim 26 , wherein the post-prandial symptom is selected from the group consisting of the flatulence, fullness, bloating, pain, and nausea.  
     
     
         28 . The method of  claim 24 , wherein said administration influences the uptake volume of the gastrointestinal tract.  
     
     
         29 . The method of  claim 24 , wherein the effective dose is from about 0.1 mg to about 10 mg daily.  
     
     
         30 . The method of  claim 24 , wherein the effective dose is about 1 mg to about 5 mg daily.  
     
     
         31 . The method of  claim 24 , wherein the effective dose is about 1 mg to about 3 mg daily.  
     
     
         32 . A method for treating functional dyspepsia in a human comprising administering about 0.1 mg to about 10 mg daily of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride to a human having functional dyspepsia, wherein the treatment influences nausea and/or pain.  
     
     
         33 . The method of  claim 32 , wherein the treatment influences the uptake volume of the gastrointestinal tract.  
     
     
         34 . The method of  claim 32 , wherein about 1-3 mg of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride is administered daily, and wherein said administration is one or more times per day.  
     
     
         35 . The method of  claim 32 , wherein about 1 mg of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride is administered daily.  
     
     
         36 . The method of  claim 35 , wherein the treatment increases the uptake volume of the gastrointestinal tract and decreases pain after the ingestion of food.